NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101
- Thursday, January 19, 2023, 7:10
- Finance
- Add a comment
RADNOR, Pa., Jan. 19, 2023 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced that it had a meeting and a written response from the Food and Drug…
About the Author
adminasapcorp has written 41811 stories on this site.